Chemical stability of admixtures containing ziconotide 25 mcg/mL and morphine sulfate 10 mg/mL or 20 mg/mL during simulated intrathecal administration

International Journal of Pharmaceutical Compounding

Volumn 12, Issue 6, 2008, Pages 553-557

  Shields, David E ^a   Aclan, Jennifer ^a   Szatkowski, Aaron ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE SULFATE; OMEGA CONOTOXIN MVIIA;

ARTICLE; DRUG DETERMINATION; DRUG MIXTURE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIMULATION;

EID: 70449680360     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. PRIALT [package insert]. San Diego, CA: Elan Pharmaceuticals, Inc.; 2007.
2. Deer T, Krames ES, Hassenbusch SJ et al. Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007; 10(4): 300-328.
3. Hassenbusch SJ, Portenoy RK, Cousins M et al. Polyanalgesic consensus conference 2003: An update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004; 27(6): 540-563.
4. Lacy CF, Armstrong LL, Goldman MP et al. Drug Information Handbook. 11th ed. Hudson, OH: Lexi-Comp; 2002.
5. Pirec V, Laurito CE, Lu Y et al. The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg 2001; 92(1): 239-243.
6. Webster LR, Fakata KL, Charapata S et al. Open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008; 9(3): 282-290.
7. Wallace MS, Kosek PS, Staats P et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008; 9(3): 271-281.
8. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005; 8(4): 257-263.
9. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy-a survey of clinical trends and decision making. J Pain Symptom Manage 2000; 20(2): S4-S11.
10. Wang YX, Gao D, Pettus M et al. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000; 84(2-3): 271-281.